The effectiveness of the use of polypeptide drugs and their effect on the metabolic parameters of oral fluid in patients with generalized periodontitis in depending on blood type

Yurii Bandrivsky¹, Orysia Bandrivska¹, Nataliia Malko², Larysa Posolenyk¹, Oksana Vydoinyk¹, Maryana Iskiv²

¹ I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
² Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Corresponding author: Yurii Bandrivsky (bandrivsky@tdmu.edu.ua)

Received 18 February 2022 ♦ Accepted 18 April 2022 ♦ Published 16 May 2022

Citation: Bandrivsky Y, Bandrivska O, Malko N, Posolenyk L, Vydoinyk O, Iskiv M (2022) The effectiveness of the use of polypeptide drugs and their effect on the metabolic parameters of oral fluid in patients with generalized periodontitis in depending on blood type. Pharmacia 69(2): 429–435. https://doi.org/10.3897/pharmacia.69.e82421

Abstract

The article presents the results of treatment of 157 patients with generalized periodontitis depending on blood type using polypeptide drugs. The concentration of total protein, C – reactive protein, IgG, TRACP, BSALP, albumin, amylase, lipase, Ca, Fe was determined in the oral fluid. The treatment allowed to reduce the content of total protein, C – reactive protein, TRACP in the oral fluid with increasing levels of calcium, Fe, BSALP, in relation to the relevant data before treatment. And also, polypeptide drugs helped to increase the level of albumin in representatives of 0 (I) and A (II) blood type in the oral fluid; contributed to a decrease: glucose, IgG with increasing activity, amylase and lipase in carriers of B (III) and AB (IV) blood type in the oral fluid, in relation to the values before treatment. The dynamics of indicators of oral fluid metabolism with the help of polypeptide drugs, convincingly proves the effectiveness of their use in the treatment of generalized periodontitis in patients with different blood type.

Keywords

generalized periodontitis, polypeptide drugs, oral fluid, blood type

Introduction

Treatment and rehabilitation of patients with inflammatory diseases of periodontal tissues is one of the most difficult problems in modern dentistry, which is reflected in the huge number of proposed tools and methods, which are not always effective. Currently, dentists have come to understand that in the treatment of inflammatory diseases of periodontal tissues it is necessary to use methods aimed at restoring local tissue homeostasis and the entire pathogenetic mechanism of this pathology (Dankevych-Kharushyn et al. 2019). Along with the use of modern methods of therapeutic treatment of affected systems, it is necessary to use methods of integrated polysystemic correction at the cell-molecular level. This is due to the fact that any chronic disease is the final stage of a long patho-
Materials and methods

Treatment of patients with generalized periodontitis with polypeptide drugs was performed in 157 patients (main group): with 0 (I) blood type – 48 patients; with A (II) blood type – 43 patients; with B (III) blood type – 35 patients and with AB (IV) blood type – 31 patients. The appointment of polypeptide drugs was carried out depending on the blood type of patients and the degree of generalized periodontitis (Drucker 2020). Considering the data obtained in our previous studies (Bandrivsky et al. 2019), changes in metabolic parameters in oral fluid were of the same type for representatives of 0 (I) and A (II) blood type and B (III) and AB (IV) with varying severity of periodontitis. Therefore, the treatment was the same, but differed in the dose and frequency of polypeptide preparations for representatives of 0 (I) and A (II) blood types and B (III) and AB (IV). The control group of patients consisted of 133 people who were treated for generalized periodontitis according to conventional methods (Plessas 2014).

Thus, patients with 0 (I) and A (II) blood type and generalized periodontitis of I degree were prescribing mummy balm (Vivax Dent, Russia) – irrigation in periodontal pockets for 7 days; gel with peptide complex and “Neovitin” (Vivax Dent, Russia) – 1.teaspoon (10 g) during meals 2 times a day for 14 days. Whereas, patients with B (III) and AB (IV) blood type and generalized periodontitis of I degree were prescribed mummy balm (Vivax Dent, Russia) – irrigation in periodontal pockets for 5 days; gel with peptide complex and “Neovitin” (Vivax Dent, Russia) – gingival applications for 5 days; Revimit (NPCRIZ, Russia) – 1 teaspoon (10 g) during meals once a day for 10 days.

Patients with generalized periodontitis of II degree with 0 (I) and A (II) blood type were prescribed mummy balm (Vivax Dent, Russia) – instillation into periodontal pockets for 10 days; gel with peptide complex and “Neovitin” (Vivax Dent, Russia) – gingival applications for 10 days; Tsinsil – T (NPCRIZ, Russia) – 1 tablet 2 times a day with meals (chewing) for 14 days; Olekap (NPCRIZ, Russia) – 1 capsule 2 times a day for 7 days; Cartalax (NPCRIZ, Russia) – 2 capsules per day with meals 2 times a day for 14 days. Patients with B (III) and AB (IV) blood type and generalized periodontitis of II degree were prescribed mummy balm (Vivax Dent, Russia) – instillation in periodontal pockets for 7 days; gel with peptide complex and “Neovitin” (Vivax Dent, Russia) – gingival applications for 7 days; Tsinsil – T (NPCRIZ, Russia) – 1 tablet 2 times a day with meals (chewing) for 10 days; Olekap (NPCRIZ, Russia) – 1 capsule 2 times a day for 14 days; Cartalax (NPCRIZ, Russia) – 2 capsules per day with meals 2 times a day for 14 days.

Patients with 0 (I) and A (II) blood type with grade III generalized periodontitis were prescribed mummy balm (Vivax Dent, Russia) – instillation in periodontal pockets for 10 days; peptide complex with Neovitin (Vivax Dent, Russia) – gingival applications for 10 days; Olekap (NPCRIZ, Russia) – 1 capsule 2 times a day with meals for 7 days; Tsinsil – T (NPCRIZ, Russia) – 1 tablet 2 times a day with meals (chewing) for 14 days; Cartalax (NPCRIZ, Russia) – 2 capsules 2 times a day with meals for 14 days; Ensil (NPCRIZ, Russia) – 1 capsule 3 times a day with meals for 14 days. Patients with B (III) and AB (IV) blood type and generalized periodontitis III degree were prescribed mummy balm (Vivax Dent, Russia) – instillation into periodontal pockets for 10 days; peptide complex with Neovitin (Vivax Dent, Russia) – gingival applications for 10 days; Olekap (NPCRIZ, Russia) – 1 capsule 2 times a day with meals for 14 days; Tsinsil – T (NPCRIZ, Russia) – 1 tablet 2 times a day with meals (chewing) for 21 days; Cartalax (NPCRIZ, Russia) – 2 capsules 2 times a day with meals for 14 days; Ensil (NPCRIZ, Russia) – 1 capsule 3 times a day with meals for 14 days.

Concentrations of total protein, albumin, amylase, lipase, calcium, and Fe were determined in the oral
Results

As a result of our proposed pharmacotherapy containing a complex of polypeptide mediators, in patients with generalized periodontitis with 0 (I) blood type of the main group 1 month after treatment (Table 1) investigated a significant decrease in oral fluid C-reactive protein by 65.29%, \( p < 0.01 \), \( p_r < 0.01 \) and TRACP – by 4.67%, \( p < 0.05 \), \( p_r < 0.05 \), in relation to data before treatment. In the control group, with identical blood group, patients with generalized periodontitis, where traditional treatment measures were used to cure the disease, in this period of observations there was a decrease in oral fluid content of C-reactive protein by 30.0%, \( p_r < 0.01 \), relative to data before treatment.

Six months after treatment in patients with generalized periodontitis of the main group with 0 (I) blood group, a significant improvement in the data of all analysed parameters in the oral fluid was investigated. Thus, we found a probable decrease in concentrations: total protein – by 36.15%, C-reactive protein – by 58.68%, TRACP activity – by 11.05%, \( p < 0.01 \), \( p_r < 0.01 \) against the background of increasing in the oral fluid albumin content – by 35.48%, \( p < 0.05 \), calcium – by 76.05%, Fe – by 29.41%, \( p < 0.05 \), \( p_r < 0.05 \), BSALP activity – by 27.27%, \( p < 0.01 \), \( p_r < 0.01 \). In the control group, after 6 months of follow-up, the values of the analysed indicators of oral fluid metabolism did not differ statistically significantly from the data before treatment, \( p_r > 0.05 \). At the same time, the content of C-reactive protein in the oral fluid of the subjects exceeded the data before treatment by 23.3%, \( p > 0.05 \).

One year after treatment in patients with generalized periodontitis with 0 (I) blood type of the main group, as a result of our proposed treatment with polypeptide drugs, there was a positive dynamics of the analysed metabolic parameters of oral fluid, which was characterized by a significant decrease in levels of total protein by 34.27%, C-reactive protein – by 76.05%, Fe – by 76.05%, \( p < 0.05 \), \( p_r < 0.05 \), calcium – by 92.96%, \( p < 0.05 \), BSALP activity – by 27.27%, \( p < 0.01 \), \( p_r < 0.01 \). In the control group, after 6 months of follow-up, the values of the analysed indicators of oral fluid metabolism did not differ statistically significantly from the data before treatment, \( p_r > 0.05 \). At the same time, in patients with generalized periodontitis of the control group, where traditional treatment measures were used to treat the disease, the values of the analysed parameters were equal to the data before treatment, \( p_r > 0.05 \).

At the same time, in this group there was a significant increase in the concentration of C-reactive protein in the oral fluid, which exceeded the data before treatment by 44.17%, \( p < 0.01 \).

When using our proposed treatment complex containing polypeptide drugs of local and general action for the treatment of generalized periodontitis in patients with A (II) blood type, was positive changes in the values of individual indicators of oral fluid metabolism (Table 2) in different treatment periods.

Table 1. Dynamics of values of protein, mineral, bone metabolism in the oral fluid of patients with generalized periodontitis with 0 (I) blood type, in different treatment periods.

| Indicators          | Before treatment | 1 month after treatment | 6 months after treatment | 1 year after treatment |
|---------------------|------------------|-------------------------|-------------------------|------------------------|
| Total protein, g/l  | 1,13±0.16        | 2,15±0.15               | 2,08±0.14               | 1,93±0.13              |
| C-reactive protein, g/l | 1,21±0.09   | 0,42±0.06**            | 0,50±0.06**            | 0,63±0.07**           |
| Albumin, g/l        | 0,31±0.03        | 0,36±0.03               | 0,42±0.04**            | 0,45±0.04**           |
| Ca, mmol/l          | 0,71±0.15        | 1,05±0.20               | 1,25±0.20***           | 1,57±0.22***          |
| Fe, mmol/l          | 0,51±0.04        | 0,59±0.04               | 0,66±0.04***           | 0,72±0.05**           |
| TRACP, ng/ml        | 3,44±0.05        | 3,30±0.04**             | 3,60±0.03**            | 2,82±0.03**           |
| BSALP, ng/ml        | 3,45±0.05        | 3,45±0.05               | 3,54±0.05              | 3,60±0.06**           |

Notes:

- \( ^a \) values of indicators in patients of the main group
- \( ^b \) values of indicators in patients of the control group
- \( ^* p < 0.05 \), \( ^** p < 0.05 \) – significant difference in the values of parameters in patients of the main group in relation to the data before treatment.
- \( ^* p < 0.01 \), \( ^** p < 0.05 \) – significant difference in the values of parameters in patients of the control group in relation to the data before treatment.
Table 2. Dynamics of values of protein, mineral, bone metabolism in the oral fluid of patients with generalized periodontitis with A (II) blood type, in different treatment periods.

| Indicators | Before treatment | Terms of treatment |
|------------|-----------------|--------------------|
|            | 1 month after   | 6 months after     | 1 year after       |
|            | treatment       | treatment          | treatment          |
| Total protein, g/l | 2.59±0.30       | 1.80±0.26          | 1.45±0.24          |
| C-reactive protein, g/L | 1.47±0.17   | 0.68±0.14          | 0.60±0.13          |
| Albumin, g/l | 1.46±0.17       | 0.73±0.16          | 1.28±0.16          |
| Ca, mmol/l | 1.24±0.06       | 1.30±0.07          | 1.92±0.06          |
| Fe, mmol/l | 1.25±0.06       | 1.25±0.06          | 1.16±0.05          |
| TRACP, ng/ml | 0.68±0.07     | 1.08±0.07**        | 1.10±0.08          |
| BSALP, ng/ml | 0.67±0.07     | 0.82±0.08          | 0.94±0.06          |
| Lipase, (U/l) | 0.54±0.05     | 0.68±0.05          | 0.94±0.06**        |
| Amylase, (U/l) | 3.37±0.07     | 3.17±0.07**        | 2.93±0.06**        |
| IgG, (g/l) | 2.40±0.05       | 2.68±0.06**        | 2.89±0.07**        |
| Total protein, g/l | 2.24±0.06     | 2.57±0.05          | 2.40±0.05          |
| C-reactive protein, g/L | 2.60±0.30     | 1.78±0.28          | 1.63±0.29          |
| Albumin, g/l | 1.24±0.06       | 1.30±0.07          | 1.92±0.06          |
| Ca, mmol/l | 1.25±0.06       | 1.25±0.06          | 1.16±0.07          |
| Fe, mmol/l | 0.67±0.07       | 0.82±0.08          | 0.94±0.06          |
| TRACP, ng/ml | 0.68±0.07     | 1.08±0.07**        | 1.10±0.08          |
| BSALP, ng/ml | 0.67±0.07     | 0.82±0.08          | 0.94±0.06          |
| Lipase, (U/l) | 0.54±0.05     | 0.68±0.05          | 0.94±0.06**        |
| Amylase, (U/l) | 3.38±0.07     | 3.13±0.07          | 3.24±0.07          |
| IgG, (g/l) | 2.40±0.05       | 2.57±0.05          | 2.24±0.04          |

Notes:

- *p<0.01, **p<0.05 – significant difference in the values of parameters in patients of the main group in relation to the data before treatment;
- *p<0.01, **p<0.05 – significant difference in the values of parameters in patients of the control group in relation to the data before treatment.

Thus, 1 month after treatment, in patients of the main group of the study was determined a probable decrease in the content of C-reactive protein by 53.74%, with an increase in calcium by 58.82%, relative to baseline, p<0.01, p<0.05. It was noted that during this period of research in the main group significantly improved the values of bone metabolism of oral fluid, which was characterized by a decrease in TRACP activity by 5.94%, p<0.05, p<0.01, with increasing BSALP activity – by 11.67%, p<0.01, p<0.05, relative to pre-treatment data. The remaining values of oral fluid metabolism, although had a positive dynamic, but did not differ statistically significantly from the reference data, p>0.05. In the control group of patients with generalized periodontitis, 1 month after treatment, the values of the parameters of oral fluid metabolism did not change and were equal to the data before treatment, p>0.05.

Six months after treatment, patients with generalized periodontitis of the main group with A (II) blood group were determined for a significant decrease in the values of protein metabolism of oral fluid in relation to data before treatment: total protein – by 40.54%, p<0.05, p<0.01, C-reactive protein – by 59.18%, p<0.01, with increasing albumin levels – by 56.45%, p<0.01. At the same time, we studied the improvement of mineral metabolism of oral fluid, which was characterized by an increase in calcium and Fe levels relative to baseline 61.76%, p<0.01, and 74.07%, p<0.01, p<0.05, respectively. At this time, the study in patients of the main group were determined by further improvement of markers of bone metabolism of oral fluid, which was due to a decrease in oral fluid TRACP activity – by 13.06%, with increasing BSALP activity – by 20.42%, p<0.01, p<0.05, for reference data. In the control group, 6 months after treatment, a probable decrease in the concentration of total protein in the oral fluid were determined – by 55.38%, p<0.05, relative to the data before treatment. In this case, the remaining analyzed parameters of oral fluid in patients of the control group was equal to the data before treatment, p>0.05.

Twelve months after treatment in patients with generalized periodontitis with A (II) blood type of the main group, the preservation of positive dynamics of the values of all analysed parameters of oral fluid metabolism was observed. Thus, in this period of research in the main group decreased the concentration of protein metabolism products: total protein – by 36.68%, p<0.05, p<0.05, C-reactive protein – by 51.0%, with increase in albumin content – by 24.19%, p<0.01, relative to before treatment data p<0.01. The improvement of mineral metabolism of oral fluid was accompanied by an increase in concentrations of calcium – by 70.59% and Fe – by 90.74%, p<0.01, p<0.01, relative to baseline. At the same time, we found in the oral fluid of the main group a decrease in the level of TRACP activity – by 14.55% against the background of increasing BSALP activity – by 28.75%, relative to reference data, p<0.01, p1<0.01. In subjects of the control group, 1 year after treatment, the values of the analysed parameters of oral fluid were equal to the data before treatment, p>0.05. At the same time, was determined a significant decrease in the concentration of Fe in the oral fluid (by 6.25%), relative to the data before treatment, p<0.05.

A study indicators of oral fluid metabolism, in patients with generalized periodontitis with B (III) blood type, showed (Table 3) that when using our treatment regimen containing polypeptides of general and local action, 1 month after treatment in the patients of main group in the oral fluid significantly increased the level of calcium – by 34.25%.

Table 3. Dynamics of values of protein, mineral, bone metabolism in the oral fluid of patients with generalized periodontitis with B (III) blood type, in different treatment periods.

| Indicators | Before treatment | Terms of treatment |
|------------|-----------------|--------------------|
|            | 1 month after   | 6 months after     | 1 year after       |
|            | treatment       | treatment          | treatment          |
| C-reactive protein, (g/L) | 0.74±0.18     | 0.61±0.17          | 0.40±0.08**        |
| IgG, (g/L) | 0.73±0.18       | 0.68±0.18          | 0.64±0.08          |
| Albumin, (mmol/L) | 0.37±0.05     | 0.34±0.04          | 0.27±0.04          |
| Amlyase, (U/l) | 50.34±10.50   | 55.89±10.75        | 65.10±15.00        |
| Lipase, (U/l) | 5.50±0.40     | 5.95±0.36          | 6.15±0.36          |
| Glucose, (mmol/L) | 0.68±0.04    | 0.60±0.13          | 0.36±0.05**        |
| Ca, (g/l) | 0.73±0.03       | 0.98±0.04*         | 1.20±0.05**        |
| Fe, (g/l) | 0.75±0.03       | 0.85±0.04**        | 0.82±0.04          |
| TRACP, (ng/ml) | 2.54±0.40     | 2.58±0.39          | 5.07±0.37          |
| BSALP, (ng/ml) | 2.82±0.07     | 2.34±0.07          | 2.48±0.08**        |

Notes:

- *p<0.01, **p<0.05 – significant difference in the values of parameters in patients of the main group in relation to the data before treatment;
- *p<0.01, **p<0.05 – significant difference in the values of parameters in patients of the control group in relation to the data before treatment.
relative to the data before treatment, p<0,05, p>0,05. At the same time, there was an improvement in the values of markers of bone metabolism in oral fluid, which was characterized by a probable decrease in TRACP activity – by 9,10%, p<0,01, p<0,05. In the control group, where traditional treatment measures were used to treat generalized periodontitis, 1 month after treatment, was observed an increase in calcium in oral fluid – by 13,33% compared to baseline, p<0,05. At the same time, in this period of observations, the values of the remaining studied parameters were equal to the data before treatment in both study groups, p>0,05.

Six months after treatment in the patients of main group with B (III) blood type, there was a significant improvement in the values of the studied parameters of oral fluid. At the same time, the improvement of protein metabolism of oral fluid was characterized by a decrease in the content of oral fluid: C-reactive protein – by 45,95%, p<0,05, p<0,05, and IgG – by 27,03%, p > 0,05; of carbohydrate metabolism: increase in amylase activity – by 29,32%, p > 0,05; of mineral metabolism: increasing the concentration of calcium – by 64,38%, p<0,01, p<0,01; of bone metabolism: a decrease in TRACP activity – by 13,20%, p<0,01, p<0,01, with an increase in BSALP activity – by 10,71%, p<0,05, p>0,05, in relation to data to treatment. The level of lipase activity in oral fluid increased – by 11,82% relative to pretreatment data, p>0,05, p<0,01. In patients of the control group, 6 months after treatment, the value of the studied parameters of oral fluid was equal to data before treatment, p<0,05. It was noted, that in the patients of control group at this period of the study probably increased the activity of TRACP in oral fluid, which was 6,76%, above the reference values, p<0,05.

After 1 year of follow-up, in the patients of main group with B (III) blood type remained positive dynamics of the values of the analysed parameters of oral fluid metabolism. We observed that the level of C-reactive protein was – 51,35%, p<0,05, IgG – 43,24%, p<0,01, IgM, p<0,01, below baseline. At the same time, the activity of amylase in the oral fluid of the patients of this group was – 71,11%, p<0,05, p<0,01, higher than before treatment. It was noteworthy that the activity of lipase increased by 21,09%, p<0,05, and was significantly higher than in the control group, p>0,01. At the same time, the glucose level decreased by 64,71%, p<0,05, increased in calcium levels – by 90,41%, p<0,01, p<0,01, Fe – by 24,14%, p<0,01, p>0,05 and BSALP – by 16,07%, with a decrease in TRACP activity – by 18,48%, p<0,01, p<0,01, in relation to treatment data. In patients of the control group of this study period, the parameters of mineral metabolism probably deteriorated, which was characterized by a decreased in calcium levels – by 11,77% and Fe – by 22,03%, p<0,05, relative to baseline. At the same time, patients in the control group showed an increase in the level of TRACP activity in oral fluid – by 10,06%, p<0,01, relative to pre-treatment data. The values of the remaining studied parameters of oral fluid metabolism were equal to the reference data, p>0,05.

During studying the dynamics of the values of oral fluid parameters in patients with generalized periodontitis with AB (IV) blood type (Table 4), as a result of the using treatment complex which contained polypeptides drugs, 1 month after treatment, was observed a decreased in the oral fluid: IgG – by 25,00%, p<0,05, TRACP – by 7,31%, p<0,01, p>0,05, and increase the level of BSALP activity – by 10,82%, p<0,01, p<0,05. At the same time, the values of the remaining studied parameters of oral fluid metabolism, although had a positive dynamic, but the obtained data did not differ statistically significantly from baseline values, p>0,05. At the same time, after 1 month of observations, in the control group, where traditional methods were used for curation of generalized periodontitis, the values of the parameters studied were changing and equal to the data before treatment p<0,05.

Table 4. Dynamics of values of protein, mineral, bone metabolism in the oral fluid of patients with generalized periodontitis with AB (IV) blood type p, in different treatment periods.

| Indicators | Before treatment | 1 month after treatment | 6 months after treatment | 1 year after treatment |
|------------|------------------|-------------------------|-------------------------|-----------------------|
| C-reactive protein, (g/l) | 0,61±0,08 | 0,53±0,07 | 0,45±0,06 | 0,37±0,05** |
| IgG, (g/l) | 0,28±0,02 | 0,21±0,02** | 0,14±0,09** | 0,12±0,08** |
| Amylase, (U/l) | 52,65±8,65 | 62,76±8,70 | 73,87±8,82 | 82,86±8,83*** |
| Lipase, (U/l) | 6,91±0,80 | 7,22±0,74 | 7,48±0,68 | 8,00±0,68*** |
| Ca, (g/l) | 0,79±0,04 | 1,35±0,04 | 1,58±0,05** | 1,69±0,06** |
| Fe, (g/l) | 0,62±0,03 | 0,68±0,04 | 0,70±0,05 | 0,73±0,04** |
| TRACP, (ng/ml) | 3,42±0,06 | 3,17±0,05* | 2,92±0,04* | 2,67±0,03*** |
| BSALP, (ng/ml) | 2,31±0,05 | 2,56±0,05*** | 2,85±0,06** | 3,10±0,07** |

Notes:

a values of indicators in patients of the main group
b values of indicators in patients of the control group

*p<0,01, **p<0,05 – significant difference in the values of parameters in patients of the main group in relation to the data before treatment.

*p<0,01, **p<0,05 – significant difference in the values of parameters in patients of the control group in relation to the data before treatment.

Six months after treatment in the patients' main group with AB (IV) blood type was determined to significantly improve a number of studied values of the parameters of oral metabolism. Thus, we found a probable decrease in the concentration of IgG – by 50,00%, p<0,01, p<0,01, glucose level – by 35,48%, p<0,05, p<0,05, TRACP content – by 14,52%, p<0,01, p<0,01, and increase in levels of amylase oral fluid – by 40,30%, p>0,05, calcium – by 100%, BSALP activity – by 23,38%, p<0,01, p<0,01. At the same time, in the patients control group, in this period of research, the values of the parameters of oral fluid metabolism were equal to data before treatment, p>0,05.

After 1 year of research in patients of the main group, where for the treatment of generalized periodontitis was used polypeptide drugs, observed the preservation of positive dynamics of the studied parameters of oral fluid metabolism. At the same time, was observed a decreasing in the oral fluid content of C-reactive protein – by 39,34%,
p<0,05, IgG – by 57,14%, p<0,01, p<0,01, glucose – by 38,71%, p<0,05, TRACP – by 21,93%, p<0,01, p<0,01, in relation to treatment data. At the same period of research was determined an increase in amylase activity – by 57,38%, p<0,05, calcium levels – by 113%, p<0,01, Fe – by 17,74%, p<0,05 and activity BSALP – by 34,20%, p<0,01, p<0,01, relative to the corresponding baseline values. In this period of research, in the control group patients, the values of the analysed indicators of oral fluid metabolism did not differ statistically significantly from the data before treatment, p>0,05.

Discussion

Changes in the activity of salivary enzymes are the result of various diseases. Thus, in inflammatory and in dystrophic – inflammatory lesions of periodontal tissues there is a decrease in lysozyme, protease inhibitors, increased activity of proteolytic enzymes, proteinases (their activity correlates with the severity of the inflammatory process), alkaline and acid phosphatases; dental caries is characterized by activation of glycogen enzymes and aerobic breakdown of carbohydrates with the formation of large amounts of organic acids (Zabolotny et al. 2016). The activity of α-amylase in saliva increases in diabetes mellitus, peptic ulcer of the stomach and duodenum, chronic pancreatitis; the content of acid phosphatase increases in epidemic hepatitis (Cardoso et al. 2018).

Immune analysis of saliva is highly informative in the diagnosis of herpetic eczema type I. Some scientists (Li et al. 2018) recommend the use of slgA studies in the oral cavity to diagnose influenza virus. In catarrhal gingivitis, there is a significant correlation between the level of specific IgG in oral fluid and serum. In this disease, the concentration of tissue plasminogen activator increases in the oral fluid, which intensively breaks down not only fibrin but also the secretory component slgA, thereby reducing local resistance (Redman et al. 2016). It has been established that in people with chronic pain the content of total protein decreases, both in blood plasma and in mixed saliva.

One of the most sensitive to pathogenic factors is the immune system. Various violations of its normal activity accompany the widest range of internal and dental pathology. Not only the development but also the course and consequences of diseases depend on the state of the body's immune reactivity. According to many clinical immunologists, in modern medicine there are obvious prerequisites for the revision of tactical schemes for the treatment of pathology with impaired immune function. It is necessary to correct and prevent immunological imbalance, which can be manifested as a deficiency of certain parts of the immune system, and hyperergic reactions of the body to foreign agents, autoimmune processes (Muniz et al. 2018).

The search for alternative treatments for inflammatory periodontal tissue disease has led dentists to use antioxidants in periodontology (Chen 2017). However, in most cases, the tactics of prescribing antioxidants are empirical rather than scientifically sound. In the treatment of periodontal diseases there are still no effective and safe approaches to the use of drugs that provide prevention and treatment of pathological processes caused by free radicals.

Our proposed therapy which contained polypeptides drugs was more effective than traditional treatment regimen, and improves the metabolic properties of oral fluid, which are responsible for the induction and development of dystrophic – inflammatory processes in periodontal tissues.

Thus, the use of polypeptide drugs of general and local action in patients with different blood groups, allowed to reduce in the oral fluid content of total protein content by 35,48%, C – reactive protein – by 47,41%, TRACP – by 18,25%, with an increase in calcium – by 91,79%, Fe – by 20,95%, BSALP – by 27,64%, in relation to the relevant data before treatment, p, p<0,05; 0,01. Curation of generalized periodontitis with polypeptide drugs contributed to a decrease in the oral fluid: glucose – by 51,71%, IgG – by 50,19%; with an increase activity in the oral fluid: amylase – by 64,25% and lipase – by 18,40% in carriers of B (III) and AB (IV) blood type, in relation to the values before treatment, p, p<0,05; 0,01. Our therapy in the treatment of generalized periodontitis contributed to an increase in the level of albumin in the oral fluid in representatives of 0 (I) and A (II) blood type by 34,68%, p, p<0,05.

Normalization of prognostic – significant for a particular blood type biochemical, immunological parameters of oral fluid in patients with generalized periodontitis prove the prospects of polypeptide drugs in the treatment of generalized periodontal tissue lesions.

Conclusion

Thus, the dynamics of indicators of oral fluid metabolism with the help of polypeptide drugs of general and local action, convincingly proves the effectiveness of their use in the treatment of generalized periodontitis in patients with different blood type.

Acknowledgements

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for profit sectors.

References

Al-Askar M, AlMeharib HS, Alaqely R, Talakey AA, Alzoman H, Alshihri A (2021) The Relationship Between Periodontal Disease and ABO Blood Groups: A Cross-Sectional Study. Oral Health Preventive Dentistry 19(1): 295–299.

Bandrivskaia N, Mrochko O, Bandrivskii Iu (2014) Physical, biochemical and bacterioscopic parameters of mouth lavage in patients with periodontium diseases and working on ethanol production enterprises. Meditsina truda i promyshlennaia ekologiya 11(5): 31–34.
Bandrivsky Y, Bandrivska O, Gnid R, Minko L, Shevchuk M (2019) Indicators of markers of bone metabolism in patients with generalized periodontitis depending on blood group. Archives of the Balkan Medical Union 54(1): 72–77. https://doi.org/10.31688/ABMU.2019.54.1.10

Cardoso EM, Reis C, Manzanares-Céspedes MC (2018) Chronic periodontitis, inflammatory cytokines, and interrelationship with other chronic diseases. Postgraduate medicine 130(1): 98–104. https://doi.org/10.1080/00325481.2018.1396876

Cekici A, Kantarci A, Hasturk H, Dyke YE (2014) Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontology 2000 64(1): 57–80. https://doi.org/10.1111/prd.12002

Chen FM (2017) Periodontal Tissue Engineering and Regeneration. Chinese journal of stomatology 52(10): 610–614.

Dankeych-Kchargyshyn IS, Vynogradova OM, Malko, NV, Gnid, RM, Bandrivsky YL, Bandrivska OO (2019) Periodontal diseases and atherosclerosis [literature review]. Wiadomosci lekarskie 72(3): 462–465. PMID: 31050999

De Lima CL, Acevedo AC, Crisi DC, Tabo MR, Guerra E, De Luca Canto G (2016) Host-derived salivary biomarkers in diagnosing periodontal disease: systematic review and meta-analysis. Journal of clinical periodontology 43(6): 492–502. https://doi.org/10.1111/jcpe.12538

Demkovych A, Bondarenko Y, Shcherba V, Luchynskyi V, Vitkovskyy V, Machogan V (2021a) Quercetin effects on adaptive immune response in experimental periodontitis of bacterial-immune genesis. Pharmacia 68(4): 877–882. https://doi.org/10.3897/pharmacia.68.e70883

Demkovych A, Shcherba V, Yaremchuk O, Stokeych V, Machogan V, Luchynskyi V (2021b) Effects of flavonol quercetin on syndrome of endogenous intoxication in experimental periodontitis. Pharmacia 68(3): 627–632. https://doi.org/10.3897/pharmacia.68.e76341

Demkovych AYe, Bondarenko YUl, Fastovets OQ, Hrad AO, Hasiuik PA, Denefil OV (2021c) State of collagenolysis in experimental periodontitis of bacterial-immune genesis and its correction with flavonol. Medicina Perpektivi 26(2): 26–32. https://doi.org/10.26641/2307-0404.2021.2.234488

Drucker DJ (2020) Advances in oral peptide therapeutics. Nature reviews. Drug discovery 19(4): 277–289. https://doi.org/10.1038/s41573-019-0053-0

Ersin Kalkan R, Öngöz Dede F, Gökmenoğlu C, Kara C (2018) Salivary fetuin-A, S100A12, and high-sensitivity C-reactive protein levels in periodontal diseases. Oral diseases 24(8): 1554–1561. https://doi.org/10.1111/odi.12927

Kheirmand-Parizi M, Akbari H, Malek-Mohamadi M, Kakoei S (2019) Association of salivary levels of immunoglobulin-a and amylase with oral-dental manifestations in patients with controlled and non-controlled type 2 diabetes. Oral health 19(1): e175. https://doi.org/10.1186/s12903-019-0868-4

Lahdentausta L, Jau P, Mäntylä P (2018) Saliva and serum biomarkers in periodontitis and coronary artery disease. Journal of clinical periodontology 45(9): 1045–1055. https://doi.org/10.1111/jcpe.12976

Leite S, Casanovas RC, Rodrigues VP (2019) The effect of nonsurgical periodontal therapy on hepcidin and on inflammatory and iron marker levels. Brazilian oral research 9(33): e0055. https://doi.org/10.1590/1807-3107bor-2019.vol33.0055

Li S, Schmalz G, Schmidt J, Krause L, Haak R, Ziebolz D (2018) Antimicrobial peptides as a possible interlink between periodontal diseases and its risk factors: A systematic review. Journal of Periodontal Research 53(2): 145–155. https://doi.org/10.1111/jre.12482

Lopez-Lacomba D, Roa-Lopez A, Gonzalez-Jaranay M, Gómez-Moreno G, Moreu G (2017) Periodontal and biochemical bone metabolism assessment on a chronic oral coagulation population treated with dicoumarins. Medicina oral, patologia oral y cirugia bucal 22(2): 258–263. https://doi.org/10.4317/medoral.21567

Muniz F, Taminski K, Cavagni J, Celeste RK, Weidlich P, Rössing CK (2018) The effect of statins on periodontal treatment—a systematic review with meta-analyses and meta-regression. Clinical oral investigations 22(2): 671–687. https://doi.org/10.1007/s00784-018-2354-9

Orlov AI (2015) Structure of nonparametric statistics (generalizing article). Industrial laboratory. Diagnostics of materials 81(7): 62–72.

Plessas A (2014) Non-surgical periodontal treatment: review of the evidence. Oral Health and Dental Management 13(1): 71–80.

Redman RS, Kerr GS, Payne JB (2016) Salivary and serum procalcitonin and C-reactive protein as biomarkers of periodontitis in United States veterans with osteoarthritis or rheumatoid arthritis. Biotechnic & histochemistry: official publication of the Biological Stain Commission 91(2): 77–85. https://doi.org/10.3109/10520295.2015.1082625

Zabolotny TD, Bandrivsky YL, Dyrk VT (2016) Local and systemic immunity in patients with different course of generalized periodontitis. Stomatologia 95(6): 23–25. https://doi.org/10.17116/stomat201695623-25